Alkem Laboratories Ltd. to launch State of the Art Technology for Diabetic Foot Ulcer Management for the first time in India

The solution would be based on disruptive 4D Bioprinting technology, which would be used to treat deep, non-healing chronic wounds and is expected to be launched in the Indian market in the latter half of 2022 post regulatory approval.

This advanced technology for DFU management has a high scope of preventing amputations in diabetic patients. This technology will be available at affordable rates to Indian patients at a time when there is no definitive treatment for DFU in India.

India currently has approximately 77 mn diabetes patients, the second highest in the world. A diabetic foot ulcer is one of the most significant and devastating complications of diabetes and is defined as a foot affected by ulceration that is associated with neuropathy and/or peripheral arterial disease of the lower limb in a patient with diabetes.

Approximately, 12-15% with diabetes suffer from DFU at least once in a lifetime. 5-24% of them will finally lead to limb amputation within 6-18 months after the first evaluation. The risk of foot ulceration and limb amputation increases with age and the duration of diabetes.

Alkem has collaborated with Rokit Healthcare Inc. to commercialize the technology in India to help reduce amputation amongst DFU patients considering the negative impact of amputation on a patient's quality of life and the associated economic burden on the healthcare system.

Sandeep Singh, Managing Director, Alkem Laboratories Ltd. , stated, "In India, Diabetes is one of the major healthcare challenges. The challenge in itself is so huge that diabetic foot ulcers often get ignored. Approximately 1 lac people have to undergo amputation every year and compromise on their quality of life. To address the problem, Alkem has collaborated with Rokit Healthcare Inc., a global regenerative solutions company, to bring out novel solutions for the management of diabetic foot ulcers."

Adding further, Sandeep asserted, "Alkem, over the years, has always been at the forefront in delivering high-quality patient care, through its innovation and patient-centric initiatives."

Established in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523) is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales (Source: IQVIA March 2021). The Company also has presence in more than 40 international markets, with the United States being its key focus market.

For more information on Alkem Laboratories Ltd., please visit www.alkemlabs.com

CONTACT: Ankit Sharma, drankit@hhconnect.in, 9873597971

This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)